IDH1 and colorectal carcinoma: Therefore, despite clear biological differences between CRC and the malignancies with a high prevalence of IDH mutations, cautious exploration of the efficacy of mutant IDH inhibitors and DNA demethylating agents is arguably warranted in IDH‐mutant CRCs.